Comparative Pharmacology
Head-to-head clinical analysis: SYNJARDY versus XULTOPHY 100 3 6.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNJARDY versus XULTOPHY 100 3 6.
SYNJARDY vs XULTOPHY 100/3.6
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Empagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin inhibits DPP-4, increasing incretin hormone levels (GLP-1, GIP), which stimulate insulin release and decrease glucagon secretion.
Xultophy 100/3.6 is a combination of insulin degludec (a long-acting basal insulin analog) and liraglutide (a GLP-1 receptor agonist). Insulin degludec binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic glucose production. Liraglutide activates GLP-1 receptors, increasing insulin secretion, decreasing glucagon secretion, and slowing gastric emptying.
Initial: 5 mg empagliflozin/1000 mg metformin hydrochloride extended-release orally twice daily with meals. Titrate based on glycemic control, up to maximum of 25 mg/2000 mg per day (given as 12.5 mg/1000 mg twice daily).
Subcutaneous injection once daily, starting at 10 units (10 units insulin degludec and 3.6 mcg liraglutide). Titrate by 2 units every 3-4 days based on fasting plasma glucose to a maximum of 50 units daily.
None Documented
None Documented
Empagliflozin: terminal half-life ~12.4 hours (supports once-daily dosing). Metformin: terminal half-life ~6.2 hours in plasma, but prolonged to ~17.6 hours in whole blood due to RBC binding; clinical effect duration aligns with daily dosing.
Insulin degludec: ~25 hours (range 22-28 hours); liraglutide: ~13 hours. The ultra-long half-life of insulin degludec allows once-daily dosing with flat activity profile.
Renal: ~95% of empagliflozin as unchanged drug; ~20% of metformin as unchanged drug via glomerular filtration and tubular secretion. Fecal: <1% for empagliflozin; ~30% of metformin as unchanged drug. Biliary: negligible.
Renal: insulin degludec and liraglutide are cleared primarily via degradation, with less than 2% excreted unchanged renally. Fecal: negligible.
Category C
Category C
Antidiabetic
Antidiabetic